7
Labeling
Change: Orlistat Jan 2007
Precautions:
General
Substantial weight loss can increase risk of cholelithiasis
Clinical
trial of type 2 Diabetes prevention:
orlistat: 47/1649 (2.9%)
placebo:
30/1655 (1.8%)
Incidence
of cholelithiasis similar at similar amounts of weight loss
Postmarketing reports:
pancreatitis